ODAC Chairman Rebukes Pfizer, Data Monitoring Committee Over Sutent Trial Conduct

The actions by Pfizer and its independent Data Monitoring Committee in terminating a Sutent clinical trial may have benefitted the study’s placebo subjects, but were a disservice to the larger community of patients with pancreatic neuroendocrine tumors, the chairman of FDA’s Oncologic Drugs Advisory Committee said April 12.